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Abstract
Background—Coronary artery restenosis is an important side
effect of percutaneous coronary intervention. Computational
models can be used to better understand this process. We
report on an approach for validation of an in silico 3D model
of in-stent restenosis in porcine coronary arteries and
illustrate this approach by comparing the modelling results
to in vivo data for 14 and 28 days post-stenting.
Methods—This multiscale model includes single-scale models
for stent deployment, blood ﬂow and tissue growth in the
stented vessel, including smooth muscle cell (SMC) prolifer-
ation and extracellular matrix (ECM) production. The
validation procedure uses data from porcine in vivo exper-
iments, by simulating stent deployment using stent geometry
obtained from micro computed tomography (micro-CT) of
the stented vessel and directly comparing the simulation
results of neointimal growth to histological sections taken at
the same locations.
Results—Metrics for comparison are per-strut neointimal
thickness and per-section neointimal area. The neointimal
area predicted by the model demonstrates a good agreement
with the detailed experimental data. For 14 days post-
stenting the relative neointimal area, averaged over all vessel
sections considered, was 20 ± 3% in vivo and 22 ± 4% in
silico. For 28 days, the area was 42 ± 3% in vivo and
41 ± 3% in silico.
Conclusions—The approach presented here provides a very
detailed, location-speciﬁc, validation methodology for in
silico restenosis models. The model was able to closely match
both histology datasets with a single set of parameters. Good
agreement was obtained for both the overall amount of
neointima produced and the local distribution. It should be
noted that including vessel curvature and ECM production
in the model was paramount to obtain a good agreement
with the experimental data.
Keywords—In silico modelling, Restenosis, Model validation,
Multiscale modelling.
INTRODUCTION
Coronary artery disease is one of the most wide-
spread causes of mortality in industrialized countries.39
Coronary artery stenosis, or abnormal narrowing, can
lead to ischemia and potentially fatal heart attacks.
This narrowing is often corrected by deploying a stent
in the affected artery to keep it open and maintain
blood ﬂow.23,24 Currently, there are multiple types of
stents in use, ranging from simple bare metal stents
(BMS) to drug eluting stents (DES), and bioresorbable
vascular scaffolds (BVS).46 Other advanced designs,
such as stents that capture endothelial progenitor cells,
are also being considered.52
During the stenting procedure, the narrowed artery
is damaged by the stent struts being pressed into the
vessel wall, as well as by the expanding balloon which
is used to distend the artery and deploy the stent. This
in turn causes a healing response in the vessel wall,
which, if it becomes excessive, can cause a new nar-
rowing of the vessel, or in-stent restenosis (ISR).25,26 In
5 to 10% cases ISR requires a repeat revascularization
of the target lesion.17 Since it is formed by growth and
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proliferation of smooth muscle cells (SMCs) in the
vessel wall, the composition of a restenotic lesion is
different from the initial lesion: a restenotic lesion
mainly consists of SMCs and the extracellular matrix
(ECM) they produce.8,15,31 The initial lesion, on the
other hand, usually consists of low-density lipoprotein
(LDL), monocytes, macrophages, fat-laden foam cells
and necrotic debris accumulated in an inﬂamed region
in the presence of disturbed ﬂow.12,18,42
ISR is associated with excessive damage to the vessel
wall and with disturbed ﬂow patterns in the stented
vessel, in particular with low values of wall shear stress
(WSS).26,28,33,45 Since ISR is an important complica-
tion of stenting, which can lead to various comor-
bidities and reduced quality of life, it is studied
clinically (reviewed in Ref. 20), as well as in various
in vivo (reviewed in Ref. 22), in vitro3,19 and in sil-
ico5,6,16,30,35,41,48,55–57 models. Computational models
of ISR usually represent cells by on-lattice or freely
moving agents, but continuum-based models have also
been proposed.
Several reports in the literature have focussed on the
formulation of the modelling approach applied to
highly idealized arterial and stent geometries. Ke-
shavarzian et al.30 coupled a 3D on-lattice agent-based
model (ABM) to a ﬁnite element method (FEM) model
to calculate the strain and stress in the tissue. Zahed-
manesh et al.56 used a 2D FEM model of stent
deployment coupled with an agent-based model of
SMC proliferation and extracellular matrix (ECM)
generation (also 2D). Nolan and Lally41 modelled
growth in an off-lattice agent-based model in a 2D
circumferential section of a stented artery. Ferei-
doonnezhad et al.16 proposed a purely FEM formu-
lation of restenosis after angioplasty. Li et al.35
described a fully coupled 2D ABM-FEM framework
that bi-directionally links ﬁnite-element stress calcula-
tions to the changing cell geometry.
In the idealised approaches described above the
artery geometry is usually assumed to be cylindrical,
and either straight longitudinal segments or circular
cross-sections are considered in 2D. Since a realistic
geometry is not used, predicted outcomes from these
models have been compared to experimental data at
the whole-artery level, using averaged neointimal area
and similar metrics. A popular source of experimental
data is a paper by Schwartz et al. from 199644 (used
e.g. in Refs. 35, 41 and 57), which reports the average
amount of lumen loss in restenotic arteries at various
time points after stenting. However, many models
predict neointimal formation exclusively around the
struts. This does not agree well with the experimental
data, which shows a more even neointima.1,4,22,32 To
validate the models on a location-speciﬁc level, and to
make predictions about restenosis development in real
vessels, a more realistic arterial geometry has to be
considered, ideally comparing restenosis progression
in vivo and in silico in exactly the same arteries.
In earlier work we developed an in silico model for
in-stent restenosis. The initial version was two-dimen-
sional,48–50 which was later extended into three
dimensions to better replicate in vivo growth dynamics
and to enable more realistic stent geometries.57 In this
work, the model is extended to include ECM produc-
tion and a modiﬁed mechanical model for internal and
external elastic laminae (IEL and EEL). The EEL
separates the middle SMC-rich vessel wall layer, tunica
media, from the outer layer, tunica adventitia. The IEL
lines the inner surface of the vessel and separates tu-
nica media from the innermost layer of the vessel wall,
tunica intima, which is composed of endothelial cells.
Additionally, in this version of the model arterial
curvatures are taken into account.
The model introduced in Ref. 57 did not include
ECM production. In that version of the model,
neointimal (NI) growth was on average about 1.5 times
lower than the in vivo results for similar injury scores.
Since experimental studies report that the neointima
includes around 50–80% of ECM by volume,15,18,29
ECM production was therefore included in the model,
which is described below.
Experimental evidence suggests that neointimal tis-
sue is heterogeneous with morphologically distinct
regions observed in human peripheral restenotic le-
sions. One type of tissue is composed of loose con-
nective tissue with wide spaces between cells, and the
second type is composed of dense connective tissue
with cells closer together.53 This study also found that
zones of loose ECM are rich in proteoglycans, in
particular versican, which is involved in trapping water
in extracellular tissue together with hyaluronan. Fur-
thermore, this study found that the regions of dense
ECM are rich in collagen and either contain tightly
packed elongated SMCs or resemble ﬁbrous plaques.
Other studies suggested mechanical deformation,
such as low amplitude biaxial strain, as one of the
mechanisms for increased versican production.34,54
There is also evidence that low ﬂow promotes pro-
teoglycan production.29 In particular, however,34 re-
ports 4% strain as sufﬁcient for production of
versican-rich ECM.
Also, SMCs are not uniformly distributed in the
neointima from lumen to media. Histology shows that
there is a higher concentration of SMCs near the lu-
men, while large areas of loose ECM with few SMCs
are found away from the lumen.10,13,31 The reason for
this heterogeneity is considered to be SMC migration,
or chemotaxis, along the gradient of growth factor
concentration.30 Growth factor concentration is the
highest near the lumen, so that is where synthetic
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SMCs tend to concentrate.51 These studies serve as a
basis for the ECM model, described in detail in the
next section.
The extended model of in-stent restenosis is then
applied to stent geometries based on micro-CT scans of
stents deployed in two porcine coronary arteries,
including the curvature of the vessel, which more clo-
sely represents in vivo coronary vessels and results in
signiﬁcant secondary ﬂows and helical ﬂow patterns.
The results obtained for these stent deployments are
then compared to detailed location-speciﬁc in vivo
histological growth data obtained for the same stent
geometries.38
MATERIALS AND METHODS
General Description of the ISR Multiscale Model
In-stent restenosis is a complex process inﬂuenced
by factors acting on diﬀerent scales. To capture these
processes, a fully coupled multiscale model of ISR was
developed. The model is described in detail in a pre-
vious publication.57 Here a brief overview is provided,
with focus on the additions made to the model.
The blood ﬂow through the stented segment is
explicitly modelled, as well as growth, proliferation
and movement of SMCs, their interaction with the IEL
and EEL, and ECM production. For regeneration of
endothelial cells (ECs) an implicit model is used. All
these submodels communicate relevant data to each
other at every iteration of the agent-based growth and
proliferation model, which operates at the largest
timescale of all the single-scale models, and therefore
has the largest time step.
The relationship between the main submodels is
shown in Fig. 1: (i) agent-based stent deployment,
which captures the mechanical deformation of the
vessel wall during stent deployment and damage to the
wall caused by excessive mechanical stress and strain;
(ii) an agent-based model for restenotic processes in the
wall, which covers SMC growth and proliferation,
ECM production, EC regeneration, and also keeps all
arterial wall components in a state of mechanical
equilibrium; (iii) a blood ﬂow model, which calculates
the ﬂow inside the stented vessel.
The blood ﬂow model uses a Lattice Boltzmann
formulation to calculate the ﬂow in the channel.47 The
lattice for the blood ﬂow model is constructed by
mapping the agents from the agent-based model to
voxels. Additionally, the agent-to-voxel mapper passes
the constructed mapping to the voxel-to-agent mapper,
which uses it to calculate per-agent WSS from voxel-
based ﬂow calculated in the blood ﬂow model. The
agents that make up the vessel wall are modelled
mechanically as elastic spheres connected by springs,
and these agents also have a biological ruleset that
governs the cell growth and proliferation. The SMCs
switch to a synthetic phenotype when they are exposed
to the lumen immediately post-stenting. The growth
and proliferation of SMCs are suppressed if the cell is
contact inhibited or if the local concentration of nitric
oxide, produced by the ECs, is sufﬁciently high. The
FIGURE 1. An overview of the multiscale in-stent restenosis model, illustrating data flow between single-scale components. After
simulating stent deployment, post-stenting geometry is used as a starting point for the off-lattice agent-based simulation of
neointima formation. From agent sizes and positions, a voxel-based geometry of the vessel is constructed, which is used to
calculate flow in the vessel. The flow produces shear stress on the vessel wall, which is mapped back to the agent-based model to
inform the next iteration of neointima formation simulation. For more detail, see also Ref. 57
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stent deployment is performed by radially expanding
the stent from the vessel centreline to a predetermined
ﬁnal shape. For time integration of movement, a
variable-step 4th order Runge–Kutta solver is used.
For the simulations described in this paper, the ﬁnal
stent shape is reconstructed from in vivo post-stenting
micro-CT data. The detailed description of the model
formulation, as well as references to the experimental
works used to calibrate the model parameters, can be
found in our previous publication.57 Unless speciﬁcally
noted, the parameters of the model used here are
similar to the ones used in Ref. 57. Supplementary
Table 1 includes a list of biological parameters used in
the model, as well as their source publications.
Experimental In Vivo Data
The experimental in vivo data used to validate the
model were obtained by stenting healthy porcine
coronary vessels with oversized balloons. The in vivo
experiments were performed as a part of an earlier
study, and the experimental protocol has been reported
previously.38 In brief, the stents were deployed in right
coronary arteries (RCA) by using over-inﬂated bal-
loons to induce restenosis (approx. 1.4:1 balloon-to-
artery ratio). The stents were harvested 14 and 28 days
post-stenting, high-resolution micro-CT scans were
obtained, and three-dimensional (3D) surface meshes
of the stents were reconstructed from this data. Fol-
lowing micro-CT, the stented vessels were embedded in
methacrylate resin T8100 (TAAB Laboratories), sec-
tioned, and submitted for histology. The in vivo vessels
were ﬁxed in resin, slide-mounted and cut with a high-
speed precision saw. The cross-sections are spaced
1 mm apart, which gives a rough location along the
stent. The corresponding in silico cross-section is then
found by using stent struts as landmarks. The sections
were parallel and vertical to the line connecting the
proximal and distal ends of the stents. Full details on
the sectioning procedure can be found in Ref. 36.
Simulation Procedure
The simulation procedure is as follows: ﬁrst, agent-
based stent geometries were generated by ﬁlling the
meshes obtained from micro-CT with agents repre-
senting small volumes (30 9 30 9 30 lm) of stent
material. Then, an agent-based stent deployment
model was used to expand the agent-based stent from
inside the lumen into its original shape, similar to Ref.
57. The deployment occurs by radially expanding the
stent into its original shape and equilibrating the inter-
agent forces after the expansion is ﬁnished.
Then, the ISR simulation was executed for the
resulting conﬁguration for a set period of simulated
time. Based on the spatial positions of agents, a voxel-
based geometry of the vessel was constructed at each
iteration of the biological growth model (1 h of simu-
lated biological time). The ﬂow in the artery is updated
at each step based on the changing arterial wall
geometry, and the relevant values, such as WSS dis-
tribution, are mapped back to the agents in the vessel
wall.
Based on the experimental studies outlined in the
introduction, we propose to ignore the volume of
collagen-rich ECM for the purpose of restenosis pro-
gression, and assume the SMCs in collagen-rich
regions to be densely packed. For loose proteoglycan-
rich ECM, the following production model was
implemented: strained synthetic SMCs (> 10%
mechanical strain, selected based on the upper bound
for production of versican-rich ECM in Ref. 34) and
their daughter cells produce loose proteoglycan-rich
ECM at a constant rate until they switch back to the
contractile phenotype. The ECM is produced by these
cells in blobs, represented as agents with a volume
equal to that of a contractile SMC. The ECM agents
have the same mechanical interaction rules as the SMC
agents,57 and also the interaction between SMC and
ECM agents follows the same rules. The ECM blobs
are produced by the strained synthetic SMCs
stochastically to avoid stepwise growth (large instan-
taneous increases in neointimal area).
Stepwise growth would happen if, for example, the
ECM agents were produced on a timer, since for two
daughter cells of a single SMC the ECM production
timer would start simultaneously. Two problems with
stepwise growth are that it is unphysiological, and also
adding many neighbouring agents at a single step
would create large artiﬁcial stresses in the neointima.
The stochastic model was chosen based on the
neointimal composition values of 50–80% ECM by
volume reported in the literature.15,18,29 The proba-
bility of ECM blob production is set to P = 0.1 per
hour per SMC; on average this results in 3 blobs of
ECM produced during a cell cycle, and consequently in
60% of the local tissue being loose ECM, which is in
line with experimental estimations. The produced
ECM blobs are placed away from the lumen, relatively
to the producing SMC agent, to mimic smooth muscle
cell migration by chemotaxis, pushing the producing
cell towards the lumen (schematically illustrated in
Fig. 2).
Also, the mechanical parameters of the IEL and
EEL have been adjusted as compared to the earlier
model.57 In this version, a mechanical difference is
introduced between IEL-covered and bare SMCs.
Using this approach, when IEL ruptures from exces-
sive strain and some IEL-covered SMC agents are re-
placed with regular SMC agents (with weaker
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interaction strength), the remaining IEL-covered
agents retract from the rupture and reduce the strain in
the intact areas of IEL. Note that the strain, unlike
stress, does not directly depend on the mechanical
properties of the IEL, and the threshold value for IEL
strain has been directly characterised from experi-
ments.21 The same approach is applied to the EEL as
well, with the exception that it is only broken in the
most extreme cases. Lamina-covered SMCs in this
version of the model have two times the attraction
force between themselves compared to non-lamina-
covered, which in case of lamina rupture allows the
tissue to pull back and reduce local mechanical strain.
This addition reﬂects the tensile strength added by the
IEL and the fact that when the IEL breaks, the local
tensile strength diminishes. The ratio of tensile strength
between lamina vs. no lamina covered SMCs is arbi-
trary as the authors were unable to ﬁnd comparisons
between IEL and a single layer of SMCs in terms of
strength. Since in this model we are not interested in
the ﬁne details of arterial mechanics, this difference is
sufﬁcient to reﬂect the in vivo phenomena: the broken
IEL retracts, instead of staying in the same place, and
this exposes medial SMCs to the lumen and promotes
growth.
Additionally, the vessel geometry was modiﬁed to
reﬂect the curved shape of in vivo coronary vessels. In
these vessels curvature results in a signiﬁcant ﬂow
helicity,7 which in turn affects the local WSS. Since
WSS indirectly controls SMC proliferation and is an
important parameter in the model,40 the curvature was
added to the model geometry. Vessels were approxi-
mated with toroidal segments, with Poiseuille ﬂow at
the inlet, and a zero-gradient boundary condition on
the outlet. To avoid unphysiological axial strain in the
vessel wall pre-stenting, the radii of the agents were
scaled based on their position relative to the outer and
inner curvatures, so that in a curved vessel segment the
agents were initially in equilibrium. The vessels’s cen-
terline is assumed to be a plane curve, positioned
according to the visible residual curvature in the micro-
CT images of stents.
Stents were deployed in these segments using a
procedure similar to the one described in Ref. 57 for
straight vessels. The radius of curvature of the toroidal
segments was chosen as 28 mm. This value is in the
middle of the curvature range used in an earlier pub-
lication concerning ﬂow assessment in the same stent,7
where the range of curvatures was obtained by a 2D
spline approximation of the centroid path in the RCA
in three similar porcine models. Also, the range was
assessed to be reasonably within measurements from
single-plane coronary angiograms of the human
RCA.37 It is worth noting that in Ref. 7, the most
pronounced differences in ﬂow patterns were observed
between the straight and curved vessels, not between
different curvatures. Additional simulations were per-
formed for straight vessels of similar diameter, and
their results were compared to the results obtained for
a curved geometry.
One simulation run was performed for each con-
sidered stent. Due to the extremely large number of
agents (more than 5 million), inherent stochasticity in
the SMC model has only a minor eﬀect on the average
output values.57 Therefore, one run for each simula-
tion is considered sufﬁcient. The simulations were
performed using a 32-core Intel Xeon E5-2650
(2.00 GHz) server. The 14-day simulation took about
25 h of (wall) computational time, and the 28-day
simulation took about 42 h.
Location-Speciﬁc Comparison
For each in vivo stent (explanted after 14 and
28 days respectively), four histological sections were
chosen, spaced from the proximal to distal ends of the
stent. Since the neointimal growth is relatively smooth,
neointimal thickness for neighbouring points is
strongly correlated. Because of this, analysing addi-
tional slices located close to the existing ones does not
add much information about the neointimal growth.
Particular slides that had relatively few (< 10) stent
struts embedded were selected for ease of landmarking.
For each histological section, a corresponding sec-
tion from the simulated stented vessel was taken at the
same location. For each pair of sections, correspond-
ing struts were identiﬁed in vivo and in silico and the
neointimal thickness at each strut was measured.
Furthermore, we also measured the total NI area
for each slide. Following Refs. 7 and 27 NI area was
deﬁned as the difference between the area enclosed by
the stent struts and the lumen area. Note that this is
not the true area of the neointima, since the vessel wall
does not form a straight line between struts after
FIGURE 2. Schematic of freshly produced loose ECM blob
placement in the model (vessel lumen at the top); ECM is
placed away from the lumen to mimic SMC migration.
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stenting. However, this metric uses discrete and easily
identiﬁable reference points for the outer border (stent
strut centers) instead of the border between the
neointima and the media, which is harder to identify
visually and can introduce additional errors. Hence,
this measurement can be deﬁned unambiguously based
on clearly visible points (struts and wall-lumen bor-
der), without relying on visually identifying the
boundary between the original media and the neoin-
tima. This means that, for comparison of the lumen
loss in vivo and in silico, this deﬁnition results in a well-
deﬁned metric.
RESULTS
Stent Deployment
Stents were deployed in the toroidal vessel segments.
Due to the vessels being more curved pre-stenting than
the observed in vivo curvature of the stents, some
hinge-like local bending effects were observed at the
stent ends (Fig. 3). The deployment resulted in an
uneven strain on the epicardial (outer curve) and
myocardial (inner curve) sides of the vessels. The larger
strain on the inner curve resulted in ruptures in the IEL
during stent deployment and to heightened strain in
the tunica media, which consequently led to increased
loose ECM production relative to the outer curve,
according to the rules previously described.
FIGURE 3. Toroidal vessel segment (a) pre- and (b) post-deployment. IEL ruptures are visible on the inner curve, as well as near
some struts. SMCs—dark blue, IEL—light blue, EEL—beige, stent—light grey.
FIGURE 4. Simulated vessel wall, colored by local WSS: (a) immediately post-stenting; (b) 28 days post-stenting. Areas of high
WSS sufficient for growth arrest in our model are shown in red, areas of low WSS are in blue. Note that the growth arrest only
happens in the presence of functional endothelium, and after growth arrest the cells remain quiescent even if WSS decreases later.
cFIGURE 5. (a) superposition of a simulated and an
experimental slice of artery taken from the middle part of the
28-day vessel, areas of loose ECM in the simulated slice are in
dark red, letters denote stent strut IDs; (b, c) positions and
extent of per-strut growth in vivo and in silico for 14 and
28 days post-stenting. Struts are assigned sequential IDs (A–
H) for each slice, and neointimal thickness was measured
from the middle of each strut along the line toward the center
of the lumen. Proximal end on the left. Strut G on the proximal
slice of 14-day stent was excluded from analysis, since it was
not present on the in silico slice, possibly due to stent
deformation between micro-CT and sectioning.
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Furthermore, similar to published results,7 the WSS
was uneven on the epicardial and myocardial sides,
with larger areas of low WSS on the myocardial side
(Fig. 4a). Areas of high WSS sufﬁcient for growth
arrest in our model are shown in red, areas of low WSS
are in blue. The growth arrest happens in the model in
the presence of functional endothelium and WSS >
0.27 Pa.
Neointimal Growth
After simulating post-stenting neointimal growth
over 28 days, the vessel lumen becomes smoother
(Fig. 4b). Growth stops almost completely at this point
in the model, which is similar to the results observed in
pigs in vivo.1 Figure 5a shows a superposition of a
simulated and histological section from the middle part
of the 28-day stent. Simulated and histological images
for other sections can be found in Fig. 6.
Figures 5b and 5c shows the measured NI thickness
for stents explanted after 14 and 28 days respectively.
Struts were assigned sequential IDs (A–H) for each
slice, and NI thickness was measured from the middle
of each strut along the line toward the center of the
lumen. Strut G on the proximal slice of the 14-day
stent was excluded from analysis, since it was not
present on the in silico slice, possibly due to stent
deformation between micro-CT and sectioning.
NI area was then measured for the same set of slides
shown on Figs. 5b and 5c. Neointimal areas for each
in vivo and in silico slice are shown in Fig. 6. Relative
NI area was calculated as the ratio between NI area
and the area enclosed by the struts. The relative NI
area is shown in Fig. 7. Figure 8 shows a paired dots
plot for 14 (a) and 28 (b) days post-stenting, for in vivo
and in silico data.
Curved and Straight Vessel Geometries Result in
Diﬀerent Growth Patterns
In addition to the curved vessel described above, the
model was also applied to a similar stent in a straight
cylindrical vessel, similar to a previous publication.57
Figures 9a and 9b shows the extent of growth in a
curved (a) and cylindrical (b) geometries for the 2nd
slide of the 28-day stent, epicardial side on top. The
cylindrical vessel approximation results in loose ECM
deposits around each strut, as well as in strong pro-
trusions on the epicardial side of the vessel, which are
not observed in vivo. Figure 9c shows the ﬂow velocity
magnitude in the middle longitudinal section of both
vessels. The ﬂow in the curved vessel creates areas of
high WSS on the top side and of low WSS on the
bottom side.
DISCUSSION
The updated model for in-stent restenosis demon-
strates good agreement with in vivo experimental his-
tology data on a per-strut basis and matches the in vivo
neointimal area closely. To the best of our knowledge
this is the ﬁrst attempt to compare a complex multi-
scale model of in-stent restenosis with histological data
at such a detailed local level. This detailed comparison
allows for location-speciﬁc comparisons between
in vivo and in silico, which enables a much richer val-
idation process.
Neointimal area (and correspondingly, the patent
lumen diameter) is, together with stenosis length, one
of the most important factors for hydrodynamic
resistance and physiological signiﬁcance of a resteno-
sis. The total extent of growth in the simulation is
similar to the in vivo data, even though the detailed
local distribution of growth differs. Also, as well as in
our previous model,57 neointimal growth can be
observed far away from the struts, similarly to exper-
imental data.1,4,22,32
Many earlier restenosis models, on the other hand,
predict a very focal growth around the struts.5,35,41,48,56
This may be caused by the assumption made in these
models that the growth originates only from the places
where the stent contacts with the artery, while in our
model it also originates from rupture of the strained
IEL far away from the stent struts. Another assump-
tion that is often made is that endothelial layer is only
disturbed locally near stent struts. This does not agree
with the experimental data of Rogers et al.43 who re-
port that in en face photomicrographs of stented
arteries there are large areas of exposed media far away
from the struts, while close to the struts areas of intact
endothelium can be found, presumably where the
balloon didn’t come into contact with the artery wall
during stent deployment.
The nonuniform growth in the model reported here
is caused by several factors. The ﬁrst one is the dif-
ference in WSS in diﬀerent locations, which aﬀects the
growth inhibition. Two other factors are related to the
damage done to the wall, which is nonuniform because
the stent curvature is diﬀerent from the unstented
vessel curvature. First, this nonuniform damage causes
tears in the internal elastic lamina, which cause larger
initial proliferation. Second, it also aﬀects the initial
strain of the medial SMCs, which in our model leads to
an increased production of loose ECM.
The observed diﬀerences in per-strut thickness can
be in part due to the diﬀerence in in vivo and recon-
structed vessel curvature radius and direction, which
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FIGURE 6. Vessel slices in vivo and in silico. In silico slices are rotated to match the orientation of in vivo slides. Stent explanted
(a) 14 days; (b) 28 days post-stenting. Slides order from proximal to distal. Letters denote strut IDs, see Fig. 5. Blue areas show
neointima estimation, as described in the text. If the lumen is outside the area enclosed by the struts (see e.g., EF in the 1st in vivo
slide), the area is taken as negative. In silico images: SMCs—dark blue, IEL—light blue, EEL—beige, ECM—red, stent—light grey.
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FIGURE 6. continued
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affects the simulated damage, strain and WSS. It
should be noted that the curvature isn’t based on the
exact same animal, since that data was unavailable, but
on the average of three similar adolescent porcine
models. Additionally, a less good agreement in the
neointimal area estimation at the stent ends compared
to the middle section can be seen. This might be related
to an inaccurate representation of the post-stenting
geometry, caused by stent deployment effects, such as
focal bending and scratching of the vessel or dogbon-
ing of the stent during the deployment, since those
effects are currently not well represented in the model.
Furthermore, it is worth mentioning that both the
addition of vessel curvature and the ECM production
do not, by themselves, signiﬁcantly increase the com-
putational costs of the model, while contributing sig-
niﬁcantly to increased accuracy of the predictions. In
particular, the ECM model consists of only a few
FIGURE 7. Relative NI area for 14 and 28 days post-stenting, for in vivo and in silico data. Measurements were taken at the
locations shown in Fig. 6.
FIGURE 8. Paired dots plot for 14 (a) and 28 (b) days post-
stenting, for in vivo and in silico data. Measurements were
taken at the locations shown in Fig. 6.
FIGURE 9. (a, b) The extent of growth in a curved (a) and cylindrical (b) geometries for the 2nd slide of the 28-day stent, epicardial
side on top. Cylindrical vessel approximation results in loose ECM deposits around each strut, as well as in strong protrusions on
the epicardial side of the vessel, which are not observed in vivo. (c) flow velocity magnitude in the middle longitudinal section of
both vessels.
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straightforward rules, which are only executed once at
each time step of the biological model. To simulate a
curved vessel, however, a larger region of the vessel is
considered, compared to the straight vessel approxi-
mation, to let the ﬂow develop before entering the
stented region.
The model is able to predict the total extent of
growth closely for the case of a stented healthy porcine
artery. However, to apply the model to diseased
human arteries, several modiﬁcations and additions
have to be introduced. First, a model of an
atherosclerotic plaque has to be added, to predict its
deformation during stent deployment and the diseased
vessel morphology during the healing period. The
more complicated geometry of a diseased vessel would
also require a more detailed stent deployment simula-
tion. Second, the parameters of the model also have to
be adjusted to human physiology, reﬂecting longer
healing and reendothelialization times and diﬀerent
vessel morphology, as well as a critical assessment of
all explicit and implicit assumptions in the model,
which capture the complex biological responses in
neointima formation.
Also, after validating the model for the BMS case, it
is possible to extend it to incorporate state-of-the-art
stents, for example DES or bioresorbable scaﬀolds.
This would require extending the model with sub-
models for drug elution and for stent polymer degra-
dation. Note that for the two dimensional version of
the model results of drug eluting stents have already
been reported.50
There are some mechanisms that aﬀect the
restenosis formation, but are not included in the ISR
model. Arterial cyclic strain has been shown to have a
strong impact on endothelial cell migration and pro-
liferation, which play important roles in vascular
healing (e.g., in the ISR model the nitric oxide pro-
duced by the ECs is the main stopping condition for
SMC growth). However, in our model, endothelium
recovery is approximated as a uniform and stochastic
process, happening in the whole stented segment at
once. In an earlier publication49 this has been shown to
be a better approximation than recovery from proxi-
mal and distal ends of the stent, however it obviously
does not capture the ﬁne details of the process, and
might also contribute to the difference in per-strut
growth for in vivo and in silico scenarios.
In addition, cyclic strain amplitude has been shown
been shown to aﬀect the growth of vascular SMCs.11
SMCs’ response to both the average value of cyclic
strain and to its amplitude were tested, and reducing
the amplitude of cyclic strain from normal physiolog-
ical values, while keeping the mean strain similar,
promoted proliferation in the SMCs. This effect is not
studied in our model in detail, since for the cells in the
stented region the amplitude of cyclic strain is assumed
to be rather similar.
Myocardial contraction also may aﬀect the process
in multiple ways, one of them is by aﬀecting the
transmural pressure gradient, which causes a response
in ECs as well as in SMCs (reported e.g., in Ref. 14).
Part of this response includes production of NO in
response to interstitial ﬂow, but the levels of NO
produced in this way are several times lower than those
produced by ECs in the response to blood shear stress.
However, the biological adaptive response of the cells
to myocardial contraction, as well as reduced cyclic
strain in the stented vessel, might have a signiﬁcant
effect on post-stenting recovery and requires further
study.
One other important direction is to quantify the
eﬀects of uncertainties in the model’s inputs on the
simulation results (uncertainty quantiﬁcation) and to
assess the sensitivity of the parameters in the model on
the simulation results (sensitivity analysis). This has
already been done for a two-dimensional version of the
model.40 Most uncertainty came from the uncertainty
in the endothelium regeneration speed, followed by
uncertainty in stent deployment depth (and conse-
quently the extent of injury sustained by the vessel).
The preliminary results for the 3D model support the
hypothesis that these two parameters are also most
important in 3D, but a more detailed uncertainty
quantiﬁcation and sensitivity analysis study is
required.
So far, the current model was only applied to the case
of a stent in a single vessel. The clinically relevant case of
bifurcation stenting2 has not yet been considered. The
modelled vessel geometry is also rather simpliﬁed, not
accounting for any unevenness of the vessel surface pre-
stenting. This can partially be alleviated by using
intravascular imaging data (e.g., optical coherence
tomography (OCT) or intravascular ultrasound (IVUS)
data) to reconstruct the unstented vessel.9
The current ECM production model simpliﬁes all
details of the biology into a few generic rules. These are
suﬃcient for this case. If however the conditions
change—for example, in a more complicated geometry
where concentration proﬁles of growth factors are
diﬀerent—these rules might produce non-physiological
behaviour, and further validation of the ECM pro-
duction model is required.
Finally, a limitation of this study is that each time
point was represented by a single animal, while in a
larger population the restenotic response is likely to
vary, and for validation multiple animals have to be
considered for each time point. The stents were de-
ployed as part of a larger study where six animals were
used.38 In each animal, both RCA and LAD were
stented with similar stents. However, micro-CT and
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subsequent stent reconstruction was only performed
for two animals, and in both cases RCA was studied.
More in vivo data are required to validate this model
before applying it in, for instance, stent design studies
and/or in silico clinical trials.
CONCLUSIONS
In this paper an approach for validation of an in
silico 3D model of in-stent restenosis in porcine coro-
nary arteries is presented and illustrated by comparing
the modelling results to in vivo data for 14 and 28 days
post-stenting. This model of ISR reported here is based
on a previously published model 57 that has been ex-
tended with ECM production and applied to in vivo
stent geometries reconstructed from micro-CT. A de-
tailed location- and strut-speciﬁc comparison between
the in silico and in vivo data was performed, in addition
to comparing an integral metric of total neointimal
area in each histological slice.
The model was able to closely match both datasets
with one single set of parameters. It should be noted
that including vessel curvature and ECM production in
the model was paramount to obtain a good agreement
with the experimental data. The procedure introduced
here can enable a richer validation process for models
of in-stent restenosis, compared to using only integral
metrics such as the average neointimal area. Our future
plans are to extend the model to diseased arteries,
human physiology, and to incorporate modern stent
designs (BMS and BVS).
ELECTRONIC SUPPLEMENTARY MATERIAL
The online version of this article (https://doi.org/10.
1007/s13239-019-00431-4) contains supplementary
material, which is available to authorized users.
AUTHORS’ CONTRIBUTIONS
PZ implemented the current version of the model,
designed, and performed the simulations, analysed the
results and drafted the manuscript. AN assisted with
analysis of the histological data, helped design and
analyse the simulations, and helped draft the manu-
script. JG performed the in vivo study and provided
histological and micro-CT data. CC provided the
reconstructed stent geometries from micro-CT scans
and helped draft the manuscript. AH conceived the
study, designed the study, coordinated the study, and
helped draft the manuscript. All authors gave ﬁnal
approval for publication.
FUNDING
PZ and AGH acknowledge partial funding by the
Russian Scientiﬁc Foundation, Grant No. 14-11-
00826. AGH and AN also acknowledge partial fund-
ing from the EU Horizon 2020 programme under
Grant Agreement 675451, the CompBioMed project.
PZ also acknowledges partial funding from the EU
Horizon 2020 programme under Grant Agreement
777119, the InSilc project.
CONFLICT OF INTEREST
The authors declare that they have no conﬂict of
interest.
OPEN ACCESS
This article is distributed under the terms of the
Creative Commons Attribution 4.0 International Li-
cense (http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and
reproduction in any medium, provided you give
appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons li-
cense, and indicate if changes were made.
REFERENCES
1Amatruda, C. M., C. Bona-Casas, B. K. Keller, H. Tahir,
G. Dubini, A. G. Hoekstra, et al. From histology and
imaging data to models for in-stent restenosis. Int. J. Artif.
Organs 37:786–800, 2014. https://doi.org/10.5301/ijao.500
0336.
2Antoniadis, A. P., P. Mortier, G. Kassab, G. Dubini, N.
Foin, Y. Murasato, et al. Biomechanical modeling to im-
prove coronary artery bifurcation stenting: expert review
document on techniques and clinical implementation.
JACC Cardiovasc. Interv. 8:1281–1296, 2015. https://doi.
org/10.1016/j.jcin.2015.06.015.
3Bennett, M. R., S. Angelin, J. P. McEwan, R. Jagoe, and
A. Newby. Inhibition of vascular smooth muscle cell pro-
liferation in vitro and in vivo by c-myc antisense oli-
goeoxynucleotides. J. Clin. Investig. 93:820–828, 1994.
4Bourantas, C. V., M. I. Papafaklis, A. Kotsia, V. Farooq,
T. Muramatsu, J. Gomez-Lara, et al. Effect of the
endothelial shear stress patterns on neointimal prolifera-
tion following drug-eluting bioresorbable vascular scaffold
implantation: an optical coherence tomography study.
JACC Cardiovasc. Interv. 7:315–324, 2014. https://doi.org/
10.1016/j.jcin.2013.05.034.
5Boyle, C. J., A. B. Lennon, and P. J. Prendergast. Appli-
cation of a mechanobiological simulation technique to
stents used clinically. J. Biomech. 46:918–924, 2013. http
s://doi.org/10.1016/j.jbiomech.2012.12.014.
BIOMEDICAL
ENGINEERING 
SOCIETY
ZUN et al.580
6Caiazzo, A., D. Evans, J. L. Falcone, J. Hegewald, E.
Lorenz, B. Stahl, et al. A complex automata approach for
in-stent restenosis: two-dimensional multiscale modelling
and simulations. J. Comput. Sci. 2:9–17, 2011. https://doi.
org/10.1016/j.jocs.2010.09.002.
7Caputo, M., C. Chiastra, C. Cianciolo, E. Cutrı`, G. Du-
bini, J. Gunn, et al. Simulation of oxygen transfer in
stented arteries and correlation with in-stent restenosis. Int.
J. Numer. Method Biomed. Eng. 29:1373–1387, 2013. http
s://doi.org/10.1002/cnm.2588.
8Chaabane, C., F. Otsuka, R. Virmani, and M. L. Bocha-
ton-Piallat. Biological responses in stented arteries. Car-
diovasc. Res. 99:353–363, 2013. https://doi.org/10.1093/c
vr/cvt115.
9Chiastra, C., S. Migliori, F. Burzotta, G. Dubini, and F.
Migliavacca. Patient-speciﬁc modeling of stented coronary
arteries reconstructed from optical coherence tomography:
towards a widespread clinical use of ﬂuid dynamics anal-
yses. J. Cardiovasc. Transl. Res. 11:156–172, 2018. https://d
oi.org/10.1007/s12265-017-9777-6.
10Chieffo, A., C. Foglieni, R. L. Nodari, C. Briguori, G.
Sangiorgi, A. Latib, et al. Histopathology of clinical
coronary restenosis in drug-eluting versus bare metal
stents. Am. J. Cardiol. 104:1660–1667, 2009. https://doi.or
g/10.1016/j.amjcard.2009.07.041.
11Colombo, A., S. Guha, J. N. Mackle, P. A. Cahill, and C.
Lally. Cyclic strain amplitude dictates the growth response
of vascular smooth muscle cells in vitro: role in in-stent
restenosis and inhibition with a sirolimus drug-eluting
stent. Biomech. Model Mechanobiol. 12:671–683, 2013. h
ttps://doi.org/10.1007/s10237-012-0433-4.
12Cunningham, K. S., and A. I. Gotlieb. The role of shear
stress in the pathogenesis of atherosclerosis. Lab. Investig.
85:9–23, 2005. https://doi.org/10.1038/labinvest.3700215.
13Curcio, A., D. Torella, and C. Indolﬁ. Mechanisms of
smooth muscle cell proliferation and endothelial regenera-
tion after vascular injury and stenting. Circ. J. 75:1287–
1296, 2011. https://doi.org/10.1253/circj.CJ-11-0366.
14DeMaio, L., J. M. Tarbell, R. C. Scaduto, T. W. Gardner,
and D. A. Antonetti. A transmural pressure gradient in-
duces mechanical and biological adaptive responses in
endothelial cells. Am. J. Physiol. Heart Circ. Physiol.
286:H731–H741, 2004. https://doi.org/10.1152/ajpheart.00
427.2003.
15Farb, A., F. D. Kolodgie, J. Y. Hwang, A. P. Burke, K.
Tefera, D. K. Weber, et al. Extracellular matrix changes in
stented human coronary arteries. Circulation 110:940–947,
2004. https://doi.org/10.1161/01.CIR.0000139337.56084.3
0.
16Fereidoonnezhad, B., R. Naghdabadi, S. Sohrabpour, and
G. A. Holzapfel. A Mechanobiological model for damage-
induced growth in arterial tissue with application to in-
stent restenosis. J. Mech. Phys. Solids 101:311–327, 2017. h
ttps://doi.org/10.1016/j.jmps.2017.01.016.
17Ferna´ndez-Ruiz, I. Interventional cardiology: drug-eluting
or bare-metal stents? Nat. Rev. Cardiol. 13:631, 2016. h
ttps://doi.org/10.1038/nrcardio.2016.160.
18Garratt, K. N., W. D. Edwards, U. P. Kaufmann, R. E.
Vlietstra, and D. R. Holmes. Differential histopathology of
primary atherosclerotic and restenotic lesions in coronary
arteries and saphenous vein bypass grafts: analysis of tissue
obtained from 73 patients by directional atherectomy. J.
Am. Coll. Cardiol. 17:442–448, 1991. https://doi.org/10.10
16/S0735-1097(10)80113-5.
19Ghasemi, M., D. R. Nolan, and C. Lally. An investigation
into the role of different constituents in damage accumu-
lation in arterial tissue and constitutive model develop-
ment. Biomech. Model Mechanobiol. 17:1757–1769, 2018. h
ttps://doi.org/10.1007/s10237-018-1054-3.
20Giacoppo, D., G. Gargiulo, P. Aruta, P. Capranzano, C.
Tamburino, and D. Capodanno. Treatment strategies for
coronary in-stent restenosis: systematic review and hierar-
chical Bayesian network meta-analysis of 24 randomised
trials and 4880 patients. BMJ 351:h5392, 2015. https://doi.
org/10.1136/bmj.h5392.
21Holzapfel, G. A., G. Sommer, C. T. Gasser, and P.
Regitnig. Determination of layer-speciﬁc mechanical
properties of human coronary arteries with
nonatherosclerotic intimal thickening and related consti-
tutive modeling. Am. J. Physiol. 289:2048–2058, 2005. h
ttps://doi.org/10.1152/ajpheart.00934.2004.
22Iqbal, J., J. Chamberlain, S. E. Francis, and J. Gunn. Role
of animal models in coronary stenting. Ann. Biomed. Eng.
44:453–465, 2016. https://doi.org/10.1007/s10439-015-1414
-4.
23Iqbal, J., J. P. Gunn, and P. W. Serruys. Coronary stents:
historical development, current status and future direc-
tions. Br. Med. Bull. 106:193–211, 2013. https://doi.org/10.
1093/bmb/ldt009.
24Iqbal, J., P. W. Serruys, and D. P. Taggart. Optimal
revascularization for complex coronary artery disease. Nat.
Rev. Cardiol. 10:635–647, 2013. https://doi.org/10.1038/nr
cardio.2013.138.
25Jukema, J. W., T. A. N. Ahmed, J. J. W. Verschuren, and
P. H. A. Quax. Restenosis after PCI. Part 2: prevention and
therapy. Nat. Rev. Cardiol. 9:79–90, 2012. https://doi.org/
10.1038/nrcardio.2011.148.
26Jukema, J. W., J. J. W. Verschuren, T. A. N. Ahmed, and
P. H. A. Quax. Restenosis after PCI. Part 1: pathophysi-
ology and risk factors. Nat. Rev. Cardiol. 9:53–62, 2012. h
ttps://doi.org/10.1038/nrcardio.2011.132.
27Keller, B. K. In-stent restenosis and coronary curvature:
translational approach to computational ﬂuid dynamics,
2012.
28Keller, B. K., C. M. Amatruda, D. R. Hose, J. P. Gunn, V.
Lawford, G. Dubini, et al. Contribution of mechanical and
ﬂuid stresses to the magnitude of in-stent restenosis at the
level of individual stent struts. Cardiovasc. Eng. Technol.
5:164–175, 2014. https://doi.org/10.1007/s13239-014-0181-
y.
29Kenagy, R. D., J. W. Fischer, S. Lara, J. D. Sandy, A. W.
Clowes, and T. N. Wight. Accumulation and loss of
extracellular matrix during shear stress-mediated intimal
growth and regression in baboon vascular grafts. J. His-
tochem. Cytochem. 53:131–140, 2005. https://doi.org/10.13
69/jhc.4A6493.2005.
30Keshavarzian, M., C. A. Meyer, and H. N. Hayenga.
Mechanobiological model of arterial growth and remodel-
ing. Biomech. Model Mechanobiol. 17:1–15, 2017. https://d
oi.org/10.1007/s10237-017-0946-y.
31Kim, W. H., M. K. Hong, R. Virmani, R. Kornowski, R.
Jones, and M. B. Leon. Histopathologic analysis of in-stent
neointimal regression in a porcine coronary model. Coron.
Artery. Dis. 11:273–277, 2000. https://doi.org/10.1097/000
19501-200005000-00011.
32Kraak, R. P., H. H. de Boer, J. Elias, C. A. Ambarus, A. C.
van der Wal, R. J. de Winter, et al. Coronary artery vessel
healing pattern, short and long term, after implantation of
the everolimus-eluting bioresorbable vascular scaffold. J.
BIOMEDICAL
ENGINEERING 
SOCIETY
Location-Speciﬁc Comparison Between a 3D In-Stent Restenosis Model and Micro-CT 581
Am. Heart Assoc. 4:1–8, 2015. https://doi.org/10.1161/JA
HA.115.002551.
33LaDisa, J. F., L. E. Olson, R. C. Molthen, D. A. Hettrick,
P. F. Pratt, M. D. Hardel, et al. Alterations in wall shear
stress predict sites of neointimal hyperplasia after stent
implantation in rabbit iliac arteries. Am. J. Physiol. Circ.
Physiol. 288:H2465–H2475, 2005. https://doi.org/10.1152/a
jpheart.01107.2004.
34Lee, R. T., C. Yamamoto, Y. Feng, S. Potter-Perigo, W. H.
Briggs, K. T. Landschulz, et al. Mechanical strain induces
speciﬁc changes in the synthesis and organization of pro-
teoglycans by vascular smooth muscle cells. J. Biol. Chem.
276:13847–13851, 2001. https://doi.org/10.1074/jbc.M0105
56200.
35Li, S., L. Lei, Y. Hu, Y. Zhang, S. Zhao, and J. Zhang. A
fully coupled framework for in silico investigation of in-
stent restenosis. Comput. Methods Biomech. Biomed. Eng.
22:217–228, 2019. https://doi.org/10.1080/10255842.2018.1
545017.
36Malik, N., J. P. Gunn, C. M. Holt, L. Shepherd, S. E.
Francis, C. M. H. Newman, et al. Intravascular stents: a
new technique for tissue processing for histology,
immunohistochemistry, and transmission electron micro-
scopy. Heart 80:509–516, 1998. https://doi.org/10.1136/hrt.
80.5.509.
37Messenger, J. C., S. Y. J. Chen, J. D. Carroll, J. E. B.
Burchenal, K. Kioussopoulos, and B. M. Groves. 3D
coronary reconstruction from routine single-plane coro-
nary angiograms: clinical validation and quantitative
analysis of the right coronary artery in 100 patients. Int. J.
Cardiovasc. Imaging 16:413–427, 2000. https://doi.org/10.
1023/A:1010643426720.
38Morlacchi, S., B. K. Keller, P. Arcangeli, M. Balzan, F.
Migliavacca, G. Dubini, et al. Hemodynamics and in-stent
restenosis: micro-CT images, histology, and computer
simulations. Ann. Biomed. Eng. 39:2615–2626, 2011. http
s://doi.org/10.1007/s10439-011-0355-9.
39Murphy, S. L., J. Xu, K. D. Kochanek, S. C. Curtin, and E.
Arias. Deaths: ﬁnal data for 2015. Natl. Vital. Stat. Rep.
2017. https://doi.org/10.1136/vr.h753.
40Nikishova, A., L. Veen, P. Zun, and A. G. Hoekstra.
Uncertainty quantiﬁcation of a multiscale model for in-
stent restenosis. Cardiovasc. Eng. Technol. 9:761–774, 2018.
https://doi.org/10.1007/s13239-018-00372-4.
41Nolan, D. R., and C. Lally. An investigation of damage
mechanisms in mechanobiological models of in-stent
restenosis. J. Comput. Sci. 24:132–142, 2018. https://doi.
org/10.1016/j.jocs.2017.04.009.
42Parton, A., V. McGilligan, M. O’Kane, F. R. Baldrick, and
S. Watterson. Computational modelling of atherosclerosis.
Brief Bioinform. 17:562–575, 2016. https://doi.org/10.1093
/bib/bbv081.
43Rogers, C., D. Y. Tseng, J. C. Squire, and E. R. Edelman.
Balloon-artery interactions during stent placement a ﬁnite
element analysis approach to pressure, compliance, and
stent design as contributors to vascular injury. Circ. Res.
84:378–383, 1999. https://doi.org/10.1161/01.RES.84.4.378.
44Schwartz, R. S., A. Chu, W. D. Edwards, S. S. Srivatsa, R.
D. Simari, J. M. Isner, et al. A proliferation analysis of
arterial neointimal hyperplasia: lessons for antiproliferative
restenosis therapies. Int. J. Cardiol. 53:71–80, 1996. http
s://doi.org/10.1016/0167-5273(95)02499-9.
45Shishido, K., A. P. Antoniadis, S. Takahashi, M. Tsuda, S.
Mizuno, I. Andreou, et al. Effects of low endothelial shear
stress after stent implantation on subsequent neointimal
hyperplasia and clinical outcomes in humans. J. Am. Heart
Assoc. 5:1–13, 2016. https://doi.org/10.1161/JAHA.115.00
2949.
46Stefanini, G. G., R. A. Byrne, S. Windecker, and A. Kas-
trati. State of the art: coronary artery stents—past, present
and future. EuroIntervention 13:706–716, 2017. https://doi.
org/10.4244/EIJ-D-17-00557.
47Succi, S. The Lattice Boltzmann Equation for Fluid
Dynamics and Beyond. Oxford: Oxford University Press,
2001. https://doi.org/10.1016/0370-1573(92)90090-M.
48Tahir, H., C. Bona-Casas, and A. G. Hoekstra. Modelling
the effect of a functional endothelium on the development
of in-stent restenosis. PLoS ONE 8:e66138, 2013. https://d
oi.org/10.1371/journal.pone.0066138.
49Tahir, H., C. Bona-Casas, A. J. Narracott, J. Iqbal, J. P.
Gunn, P. V. Lawford, et al. Endothelial repair process and
its relevance to longitudinal neointimal tissue patterns:
comparing histology with in silico modelling. J. R. Soc.
Interface 11:20140022, 2014. https://doi.org/10.1098/rsif.2
014.0022.
50Tahir, H., A. G. Hoekstra, E. Lorenz, P. V. Lawford, D. R.
Hose, J. P. Gunn, et al. Multi-scale simulations of the
dynamics of in-stent restenosis: impact of stent deployment
and design. Interface Focus 1:365–373, 2011. https://doi.
org/10.1098/rsfs.2010.0024.
51Tahir, H., I. Niculescu, C. Bona-Casas, R. M. H. Merks,
and A. G. Hoekstra. An in silico study on the role of
smooth muscle cell migration in neointimal formation after
coronary stenting. J. R. Soc. Interface 12:20150358, 2015. h
ttps://doi.org/10.1098/rsif.2015.0358.
52Van Beusekom, H. M. M., G. Ertas¸, O. Sorop, P. W.
Serruys, and W. J. Van Der Giessen. The GenousTM
endothelial progenitor cell capture stent accelerates stent
re-endothelialization but does not affect intimal hyper-
plasia in porcine coronary arteries. Catheter. Cardiovasc.
Interv. 79:231–242, 2012. https://doi.org/10.1002/ccd.2292
8.
53Wight, T., S. Lara, R. Riessen, R. Le Baron, and J. Isner.
Selective deposits of versican in the extracellular matrix of
restenotic lesions from human peripheral arteries. Am. J.
Pathol. 151:963–973, 1997.
54Wight, T. N., and M. J. Merrilees. Proteoglycans in
atherosclerosis and restenosis: key roles for versican. Circ.
Res. 94:1158–1167, 2004. https://doi.org/10.1161/01.RES.
0000126921.29919.51.
55Zahedmanesh, H., and C. Lally. A multiscale mechanobi-
ological modelling framework using agent-based models
and ﬁnite element analysis: application to vascular tissue
engineering. Biomech. Model Mechanobiol. 11:363–377,
2012. https://doi.org/10.1007/s10237-011-0316-0.
56Zahedmanesh, H., H. Van Oosterwyck, and C. Lally. A
multi-scale mechanobiological model of in-stent restenosis:
deciphering the role of matrix metalloproteinase and
extracellular matrix changes. Comput. Methods Biomech.
Biomed. Eng. 17:813–828, 2014. https://doi.org/10.1080/10
255842.2012.716830.
57Zun, P. S., T. Anikina, A. Svitenkov, and A. G. Hoekstra.
A comparison of fully-coupled 3D in-stent restenosis sim-
ulations to in-vivo data. Front. Physiol. 8:284, 2017. http
s://doi.org/10.3389/fphys.2017.00284.
Publisher’s Note Springer Nature remains neutral with re-
gard to jurisdictional claims in published maps and institu-
tional afﬁliations.
BIOMEDICAL
ENGINEERING 
SOCIETY
ZUN et al.582
